Normal human immunoglobulin is manufactured from human plasma and contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. It is usually prepared from pooled plasma from not fewer than 1000 donors. Adequate doses can restore abnormally low immunoglobulin G levels to the normal range and thus help against infections. The mechanism of action in indications other than replacement therapy is not fully elucidated, but includes immunomodulatory effects.

Indications for use are numerous with critical need as well as the effectiveness of treatment variable; it is life saving for some patients for whom no alternative treatment exists while others do have clinically effective, and often more cost effective, alternatives available.

There have been global and in particular, UK supply issues with Immunoglobulin preparations, on a background of increased demand. Due to this and questions regarding cost effectiveness in some indications, intravenous Immunoglobulins (IVIg) and subcutaneous immunoglobulins (SCIg) are subject to a national Demand Management Plan.


Policy Details

Download: N/A
Compiled by: Jemma Hives, Formulary and Medicines Optimisation Pharmacist
Ratified by: Drug and Therapeutics Committee
Date Ratified: July 2022
Date Issued: August 2022
Review Date: July 2024
Target Audience: All members of clinical team at ASPH involved in prescribing, supplying and administering normal human immunoglobulin.
Contact name: Jemma Hives


Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.